Fifth &#197;land Island conference on von Willebrand disease by E. Berntorp et al.
Haemophilia. 2018;24(Suppl. 4):5–19.	 wileyonlinelibrary.com/journal/hae	 	 | 	5© 2018 John Wiley & Sons Ltd
 
Accepted: 01 March 2018
DOI: 10.1111/hae.13475
O R I G I N A L  A R T I C L E
Fifth Åland Island conference on von Willebrand disease
E. Berntorp1 | A. Ågren2 | L. Aledort3 | M. Blombäck4 | M. H. Cnossen5 |  
S. E. Croteau6 | M. von Depka7 | A. B. Federici8 | A. Goodeve9,10 |  
J. Goudemand11 | P. M. Mannucci12 | M. Mourik13 | P. T. Önundarson14 |  
F. Rodeghiero15 | T. Szántó16 | J. Windyga17
1Centre for Thrombosis and Haemostasis, Skåne University Hospital, Lund University, Malmö, Sweden
2Coagulation Unit, Department of Medicine, Division of Haematology, Karolinska University Hospital, Stockholm, Sweden
3Department of Hematology and Medical Oncology, Mount Sinai Hospital, New York, NY, USA
4Department of Molecular Medicine and Surgery, Karolinska University Hospital, Stockholm, Sweden
5Erasmus University Medical Center – Sophia Children’s Hospital Rotterdam, Rotterdam, The Netherlands
6Boston Children’s Hospital, Boston Hemophilia Center, Harvard Medical School, Boston, MA, USA
7Werlhof-Institute Hannover, Hannover, Germany
8Department of Oncology and Oncologic Hematology, Haematology and Transfusion Medicine, L. Sacco University Hospital, University of Milan, Milan, Italy
9Haemostasis Research Group, University of Sheffield, Sheffield, UK
10Sheffield Diagnostic Genetics Service, Sheffield Children’s NHS Foundation Trust, Sheffield, UK
11Department of Haematology, Lille University Hospital, Lille, France
12Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Cà Grande Maggiore Policlinico Hospital Foundation, Milan, Italy
13Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands
14Landspitali University Hospital, University of Iceland School of Medicine, Reykjavik, Iceland
15Department of Cell Therapy and Hematology, San Bortolo Hospital, Vicenza, Italy
16Coagulation Disorders Unit, Departments of Hematology and Clinical Chemistry (HUSLAB Laboratory Services), Helsinki University Central Hospital, 
Helsinki, Finland
17Department of Disorders of Hemostasis and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
Correspondence
Erik Berntorp, Centre for Thrombosis and 
Haemostasis, Skåne University Hospital, 
Lund University, Malmö, Sweden.
Email: erik.berntorp@med.lu.se
Funding information
Octapharma
The fifth Åland Island meeting on von Willebrand disease (VWD) was held on the 
Åland Islands, Finland, from 22 to 24 September 2016—90 years after the first case 
of VWD was diagnosed in a patient from the Åland Islands in 1926. This meeting 
brought together experts in the field of VWD to share knowledge and expertise on 
current trends and challenges in VWD. Topics included the storage and release of 
von Willebrand factor (VWF), epidemiology and diagnostics in VWD, treatment of 
VWD, angiogenesis and VWF inhibitors.
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1  | INTRODUC TION
In 1926, Erik von Willebrand published an article on a disorder 
“Hereditär pseudohemofili,” which later became known as von 
Willebrand disease (VWD).1 Over the next 90 years, there have been 
many advances in our understanding of the underlying mechanisms, 
pathogenesis and treatment of VWD. VWD has been reported to 
affect up to approximately 1% of the general population and is the 
6  |     BERNTORP ET al.
most common bleeding disorder. VWD is clinically heterogeneous 
and is classified into 3 main categories based on distinct quantita-
tive and qualitative abnormalities in von Willebrand factor (VWF).2-4 
Type 1 VWD is the most common form (~70%- 75% of all cases) and is 
characterized by a partial quantitative deficiency in functionally nor-
mal VWF. Type 3 VWD (~1%- 3% of cases) is characterized by a se-
vere quantitative deficiency in VWF together with very low plasma 
factor VIII coagulant activity (FVIII:C). Type 2 VWD (~20% of cases) 
is characterized by qualitative deficiencies in VWD and is further 
subdivided into 2A, 2B, 2M and 2N subtypes.
The fifth Åland Island meeting 2016, which coincided with the 
90th anniversary of the first VWD case description by Erik von 
Willebrand in a 5- year- old girl named Hjördis S from the Åland 
Islands, brought together experts in VWD to discuss the latest sci-
entific and clinical knowledge on VWD.
2  | V WF STRUC TURE AND FUNC TION
2.1 | Nanoscopic view on VWF structure and 
Weibel- Palade bodies
Weibel- Palade bodies (WPBs) are storage organelles for VWF in en-
dothelial cells (Figure 1A).5,6 After its synthesis in the endoplasmic 
reticulum, VWF pre- pro- proteins undergo cleavage and go on to 
form multimers.6 WPBs are first formed in the trans- Golgi network 
and, as WPBs develop, the stored VWF is assembled into tubules.6,7 
During maturation of the WPBs, VWF tubules grow and WPBs 
become elongated and more protein- dense.6,8,9 At the end of this 
process, other co- stored proteins are also packaged into the WPB 
granules.6 Upon stress stimulation, such as injury or inflammation, 
mature WPBs are transported to the plasma membrane.6 VWF is 
then secreted into blood vessels via exocytosis where it structur-
ally rearranges into strings to capture platelets and initiate primary 
haemostasis.6
To elucidate the mechanistic details of the WPB life cycle, bio-
genesis of WPBs was followed using various ultrastructure imag-
ing techniques10-12 (Figure 1B- D). WPBs were first depleted from 
human umbilical cord venous endothelial cells (HUVECs) by phorbol 
12- myristate 13- acetate (PMA) treatment, which induces exocytosis 
of WPBs.11 Synthesis of nascent WPBs over time was then followed 
by visualization of VWF. Confocal microscopy and transmission elec-
tron microscopy analyses of immunofluorescence- and immunogold- 
labelled VWF, respectively, showed the appearance of newly formed 
WPB- like structures containing VWF tubules after 4 hours of recov-
ery from PMA treatment.11 These findings were then confirmed 
using correlative light and electron microscopy (CLEM), which com-
bines confocal microscopy with conventional transmission electron 
microscopy, using transfected HUVECs expressing enhanced green 
fluorescent protein (EGFP)- tagged VWF propeptide10,11 (Figure 1B). 
The CLEM analysis revealed that 4 hours after transfection, early 
electron- lucent WPBs began to appear and that 6 and 8 hours 
after transfection they appeared denser and more elongated. The 
3D morphology of nascent WPBs was also investigated by electron 
tomography as well as serial block- face scanning electron micros-
copy (Figure 1C- D), where a focussed ion beam removes layers of 
sample material in between cycles of scanning electron microscopy 
imaging.11,12 This showed that WPBs are tightly associated with the 
Golgi through numerous connections during their formation. As 
WPBs develop, non- tubular VWFs are delivered from the Golgi to 
the lumen of the WPBs through these connections and once inside 
VWFs rearrange into tubules. Interestingly, the WPB- Golgi connec-
tions continue to be maintained 8 hours after transfection of the 
labelled propeptide when dense elongated WPBs are already visi-
ble.11 Findings from this nanostructure imaging study, where WPBs 
remain closely Golgi- associated until maturation, are in line with 
results from a separate study using super- resolution microscopy.13
There are several modes of VWF secretion from mature, stim-
ulated WPBs.14,15 Single WPBs can exocytose individually, and 
F IGURE  1 Visualizing the life cycle of 
WPBs at the ultrastructural level.10-12 A, 
The life cycle of WPBs. B, Correlative light 
and electron microscopy of nascent WPB 
formation. C, Serial block- face scanning 
electron microscopy imaging of WPBs 
adjacent to (yellow) and connected to (red) 
the Golgi (green). The nucleus is shown 
in blue. D, Electron tomography of WPB 
(green) with numerous connections to 
the Golgi (yellow). WPB, Weibel- Palade 
bodies
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several WPBs may fuse intracellularly to produce large secretory 
pods prior to release of VWF.16 Live- cell imaging in HUVECs con-
firmed that large secretory pods are formed through coalescence 
of multiple WPBs shortly before secretion.17 The analysis also 
revealed that VWF adopts a globular conformation immediately 
after exocytosis and remains anchored to the cell periphery for 
structural remodelling to form strings.17 Under more physiological 
conditions using a flow chamber, the extension of VWF strings 
was predominantly observed at the edge of cells, which suggests 
this structural remodelling process may be facilitated by surface 
receptors such as integrins.17 Another mode of secretion is known 
as the “lingering kiss” where smaller co- stored cargo in WPBs, 
such as interleukins, is selectively released while VWF is retained 
intracellularly.14
Genetic mutations in a discrete region of the VWF gene have 
been associated with VWD patients who are non- responders or par-
tial responders to desamino- D- arginine vasopressin (DDAVP), which 
acts to induce VWF secretion from endothelial cells.18 However, the 
mechanism underlying the response to DDAVP is likely to be very 
complex as similar mutations are found in both non- responders and 
responders.18 In a cell- based study, these VWF mutations were stud-
ied in more detail by their transient expression in HEK293 cells.19 
Key mutant phenotypes included the inability to form mature elon-
gated WPBs, retention of VWF in the endoplasmic reticulum and 
reduced VWF secretion upon PMA stimulation. These findings sug-
gest that impairment at different stages of the WPB life cycle, in-
cluding release of VWF and string formation, may play a role in the 
pathogenesis of VWD.19,20
Advances in cell imaging techniques have greatly improved our 
knowledge of the physiological and pathophysiological processes 
involved in the storage and release of VWF. Impaired VWF storage, 
release and string formation seem to be potential pathophysiological 
mechanisms in VWD.
3  | V WD EPIDEMIOLOGY AND 
DIAGNOSTIC S
3.1 | Diagnosing type 1 VWD
Although laboratory tests can generally distinguish type 1 VWD 
from other subtypes, the diagnosis of type 1 VWD remains chal-
lenging. Diagnosis of type 1 VWD is complicated by the high fre-
quency of bleeding symptoms in the general population, the overlap 
of VWF level ranges in non- VWD individuals and VWD patients, and 
the lack of a strict relationship between VWF level and the severity 
and frequency of bleeding.21-23 The continuous spectrum from se-
vere VWD to non- affected individuals presents difficulties for set-
ting decisional thresholds to distinguish those affected from those 
not affected. This is evident in the variation in reported prevalence 
estimates, which span 2- 3 orders of magnitude. The prevalence is 
estimated to be 1 in 100 based on population- based studies and 
1 in 1000 or 1 in 10 000 in specialized centres and most review 
articles.24-28
The aim of diagnosis should be to achieve a positive clinical out-
come after a diagnosis. The outcome of diagnosis can be viewed in 
terms of diagnostic utility (patient perspective) and diagnostic ac-
curacy (physician perspective).21 As clinicians, we should pursue a 
clinically useful diagnosis, which means that the diagnosis should be 
of some benefit for the patient and not simply be accurate (ie, a di-
agnosis not biased by high false- positive or false- negative rates).21 
However, this is a particularly difficult task in mild bleeding disorders 
such as type 1 VWD.
Collaborative studies on large cohorts of patients with mainly 
type 1 VWD have demonstrated the utility of a bleeding assessment 
tool (BAT) in diagnosis.29-32 In the first of these studies, an interna-
tional multicentre study (Vicenza BAT study),29 the number of bleed-
ing symptoms, especially the quantitative bleeding score, identified 
patients with type 1 VWD with a high discriminative power. Males 
and females with bleeding scores of >3 or >5, respectively, were 70 
times more likely to have VWD compared with non- affected indi-
viduals.29 Furthermore, bleeding score has been shown to predict 
bleeding risk in patients with VWD33 and to correlate with VWD se-
verity.34 Subsequent studies using modified versions of the Vicenza 
BAT have confirmed the usefulness of BATs as a screening tool 
for the diagnosis of type 1 VWD.30-32,35 In 2010, the International 
Society on Thrombosis and Haemostasis (ISTH) proposed a single 
BAT to standardize reporting of bleeding symptoms for use in adult 
and paediatric populations.36 In addition, a self- administered BAT 
based on the ISTH- BAT has been developed.37
Using the distribution of VWF in non- affected and affected in-
dividuals, the likelihood ratio of having VWD based on each class of 
VWD values can be calculated. This likelihood ratio was also use-
ful in the diagnosis of type 1 VWD in the MCMDM- 1VWD study.30 
There was a steep increment in the likelihood ratio of VWD when 
VWF antigen content (VWF:Ag) and VWF ristocetin cofactor activ-
ity (VWF:RCo) values were below 40 IU dL−1 and a fivefold decrease 
in the likelihood ratio of VWD for values above 60 IU dL−1.30 Using 
a Bayes theorem approach, a combination of likelihood ratios from 
bleeding scores, VWF:Ag level and number of family members with 
plasma VWF lower than the 2.5 percentile were shown to influence 
the final odds of VWD.38 Based on these observations, minimum cri-
teria of significantly elevated bleeding score (>3 or >5 in men and 
women, respectively) and VWF:Ag or VWF:RCo levels <40 IU dL−1 
(either confirmed or consistently reported in patient clinical records) 
have been proposed25 (Figure 2).
With these minimal criteria, the Bayesian calculation allows the 
estimation of the probability of having VWD as 80/100 (80%).25 
Using this approach, 1 in 5 of patients would be incorrectly clas-
sified, which can be reduced to 1 in 16 if the minimum criteria are 
extended to include a family member with VWF:RCo <40 IU dL−1.38 
Once the minimal criteria for VWD diagnosis have been met, the 
next step would be to conduct laboratory analysis to characterize 
the type and severity of VWD, including a DDAVP test when appro-
priate, and determine the most suitable treatment.
In summary, 90 years after the discovery of VWD, the diagnosis 
of type 1 VWD is still intriguing. Using a 2- step process for diagnosis, 
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in which minimal criteria are used to select most likely affected in-
dividuals (step 1) followed by full laboratory evaluation (step 2), may 
improve diagnosis of VWD. However, this approach needs to be val-
idated in large cohorts of patients (adults and children) with various 
types of VWD.
3.2 | Genetic diagnostics of VWD
Clinical diagnosis of VWD and differentiation between its subtypes 
can be difficult, particularly when the phenotype is ambiguous. 
Genetic diagnostics may help facilitate correct differential diagnosis 
and ensure appropriate treatment and can also be useful in genetic 
counselling and prenatal diagnostics.39
The VWF gene spans 178 kb of genomic DNA in 52 exons that 
encodes an 8.8 kb mRNA and a 2813 amino acid protein.39,40 Over 
160 normal variants of the VWF gene are known in the exons and 
closely flanking intronic sequences, and amino acid substitutions are 
reported at 30 residues.40 Until recently, genetic analysis of the VWF 
gene has been limited to Sanger DNA sequencing, which, given the 
complexity of the VWF gene, has rendered genetic analysis and data 
interpretation complex and time- intensive. However, the availability 
of next- generation sequencing (NGS) now permits rapid simultane-
ous analysis of multiple genes. Additionally, large exon deletions and 
duplications can be detected by multiplex ligation- dependent probe 
amplification and micro- array analysis. The entire VWF gene cod-
ing sequence can now be readily analysed for phenotype/genotype 
correlation.
Overall, pathogenic variants have been identified in >90% type 
3 alleles, 50%- 90% type 2 alleles and <65% type 1 alleles. The lo-
cation of key VWF mutations in type 1, 2 and 3 VWD is shown in 
Figure 3.41,42 Type 1 VWD mutations can be found throughout the 
length of VWF, 75% being missense mutations and 25% other types 
of mutations.41 A special form of type 1 VWD is “type 1C,” which 
is characterized by a rapid clearance of VWF, eg, caused by p.Ar-
g1205His (“Vicenza mutation”).43,44 Type 3 VWD is the most severe 
form of VWD with mutations found throughout the entire coding 
region of the VWF gene. Over 80% are null mutations that result in 
complete lack of VWF production.41 Type 2 VWD is subdivided into 
4 subtypes, 2A, 2B, 2M and 2N. In most cases, the multimer pro-
file is normal, but loss or gain of specific cysteine residues in the D’ 
and D3 assembly often lead to pleiotropic abnormalities where both 
reduced VWF levels and multimer abnormalities may be present. 
The key locations of VWF mutations in type 2 VWD are shown in 
Figure 4.41,42 Type 2A VWD is mostly caused by missense mutations 
predominantly in the A2 domain (exon 28) and the D3 domain (exons 
25- 27), which reduce binding to platelets. Type 2B VWD is limited 
to missense mutations in a discrete region of the A1 domain (exon 
28), which enhance binding to platelets. Missense mutations in the 
A1 and A3 domains are found in type 2M VWD, leading to reduced 
binding of VWF to platelets or collagen. VWD type 2N missense mu-
tations	predominate	in	the	D′	domain	(exons	17-	20)	and	D3	domain	
F IGURE  2 Clinical spectrum of VWD: 
implications for management. DDAVP, 
desamino- D- arginine vasopressin; FVIII, 
coagulation factor VIII; IU, international 
units; VWD, von Willebrand disease; 
VWF, von Willebrand factor; VWF:RCo, 
von Willebrand factor ristocetin cofactor 
activity
DDAVP 
trial infusion
Spontaneous bleeding, 
particularly 
mucocutaneous. 
High bleeding risk
after minor challenges.
Severe
Clearly increased 
bleeding score,
but spontaneous 
bleeding less frequent.
Intermediate
Spontaneous bleeding 
uncommon.  
Frequently uneventful
surgeries, even without 
prophylaxis.
Mild
Bleeding 
manifestations*
<10 IU dL-1
(All types)
10–30 IU dL-1
(Type 1 and 2)
30–40 IU dL-1
(Mainly type 1)
Indicative
VWF:RCo levels
Treatment
FVIII/VWF concentrates if
DDAVP unresponsive/contraindicated
or at-risk surgery 
DDAVP (if responsive)
Counselling / antifibrinolytics
Assessment of VWD clinical severity
Recommended Not required
VWD diagnosis: Increased bleeding score and VWF:RCo <40 IU dL-1Minimal diagnostic criteria
*Bleeding manifestations should be assessed according to Rodeghiero F, et al.  J Thromb Haemost. 2010;8:2063-2065. 
F IGURE  3 Location of key VWF mutations in type 1, type 2 and 
type 3 VWD. VWD, von Willebrand disease; VWF, von Willebrand 
factor
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(exons 24- 25), leading to reduced binding of VWF to FVIII. If no mu-
tations are found in this region, type 2N VWD can be excluded and 
the F8 gene should be screened for haemophilia A.
Modern molecular genetic analysis has greatly enhanced our 
understanding of the molecular basis of VWD and its subtypes and 
continues to contribute considerably to improving differential diag-
nosis and management of patients with VWD.
3.3 | Phenotype/genotype correlation of patients 
with VWD
The Centre de Référence de la Maladie de Willebrand (CRMW; 
French reference centre for VWD) was initiated in 2006 and is a 
collaboration of the main haemostasis departments in France (~50 
university hospitals). The CRMW provides a unique national biologic 
platform for highly specialized analyses of phenotype, genotype and 
phenotype- genotype correlations in patients with VWD.
To investigate the impact of phenotype- genotype on the VWD 
classification, data have been analysed for 1167 patients enrolled 
between 2007 and 2012.45 Patients previously diagnosed locally 
with VWD were included in the study. VWD phenotype was clas-
sified as type 1: VWF levels <30 IU dL−1 together with VWF:RCo 
(or VWF:CB)/VWF:Ag and FVIII:C/VWF:Ag ratios >0.6; type 2: de-
creased or normal VWF levels with a discrepancy between the an-
tigenic and the functional levels (VWF:RCo (or VWF:CB)/VWF:Ag 
or	 FVIII:C/VWF:Ag	 ratios	 ≤0.6);	 or	 type 3: VWF levels <5 IU dL−1. 
Upon entry into the study, first- level phenotypic assays of VWF:Ag, 
VWF:RCo, FVIII:C, platelet count, activated partial thromboplas-
tin time, ristocetin- induced platelet aggregation (RIPA) and plate-
let function analyser- 100 occlusion time were performed locally. 
Second- level VWF assays were performed by the CRMW biologic 
platform and included VWF multimeric distribution, VWF binding 
to platelet glycoprotein Ib, collagen and FVIII, and, in some patients, 
analysis of proteolytic fragments. Genomic DNA was screened for 
sequence variations by direct sequencing of the VWF gene and, in 
some cases, by multiplex ligation- dependent probe amplification. 
Human Genome Variation Society (HGVS) nomenclature (www.
hgvs.org/mutnomen/) was used for the sequence variations. The 
final classification of VWD was established by a working group 
taking into account the detailed phenotype, genotype, response to 
DDAVP (if available) and familial pedigree. The classification could 
be revised to reflect newly acquired information.
Among the 1167 patients tested for both phenotype and geno-
type, there were 670 index cases (from 670 unrelated families) and 
497 affected family members. The gender ratio (F/M) of the 1167 pa-
tients was 1.46 and age ranged from 6 months to 90 years (median 
34 years). The percentage of O blood group was 56%, and in those 
patients, mean VWF:Ag levels were 19 IU dL−1 lower than in patients 
with non- O blood group. The majority of patients were caucasian 
(90%), and 10% were Afro- Caribbean.
Of the 670 index cases, 167 (25%) were classified as type 1 VWD, 
442 (66%) as type 2 VWD and 54 (8%) as type 3 VWD (Figure 5). The 
distribution of VWD subtypes was similar in the overall population. 
The percentage of patients with type 1 VWD (25%) was lower than 
previous estimates (~75%).40 This may be due to the stringent inclu-
sion criteria (VWF <30 IU dL−1) and the extensive identification of 
type 2 VWD in the CMRW cohort, which could otherwise have been 
classified as type 1 VWD. This is consistent with a European study in 
patients with type 1 VWD in which one- third of patients could have 
been reclassified as having type 2 VWD.35 Data from the CRMW are 
generally consistent with those from a multicentre Spanish study.46 
The percentage of patients with type 1 and type 3 VWD were similar 
in the CRMW and Spanish studies, although there was some varia-
tion in the distribution of type 2 subtypes.45,46
Of the 167 index cases with type 1 VWD, 88 (53%) had type 1 
mutations associated with a decreased synthesis/secretion of VWF, 
33 (20%) exhibited mutations inducing an accelerated VWF clear-
ance, 6 (3.5%) had propeptide cleavage site mutations, and 34 (20%) 
exhibited heterozygous mutations and were considered as type 3 
carriers; no mutation was found in 6 type 1 VWD patients (3.5%).45 
In the 54 type 3 VWD patients, 61 distinct sequence variations were 
identified that were novel mutations in two- thirds of cases. These 
sequence variations were spread over the VWF gene, with a predom-
inance at the N- terminal part of VWF (D domains), and consisted 
F IGURE  4 Key locations of VWF mutations in type 2 VWD. 
VWD, von Willebrand disease; VWF, von Willebrand factor
D1 assembly D2 assembly D’D3 assembly D4 assembly
ex 11-16 ex 52ex 25-27 ex 28 ex 36, 41ex 6-7
F IGURE  5 Distribution of VWD types in 670 index cases.45 
VWD, von Willebrand disease
Type 1: 25%
Type 2: 66%
Type 3: 8%
1
2A
2B
2M
2N
3
VWD
25%
18%
17%
19%
12%
8%
1%
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mainly of truncating mutations leading to silent alleles (82%) and a 
lower percentage of missense mutations (18%).45 The number of pa-
tients with type 3 VWD analysed from the CRMW database has now 
increased to 75 patients, and 72 different mutations were identified 
throughout the VWF gene (25 (37%) located in the propeptide region 
and 47 (65%) were novel mutations). Among the 75 patients, 27 (36%) 
were homozygous and 48 (64%) were compound heterozygous. For 
9 patients (12%), only 1 VWF mutant allele was identified. In the 442 
patients with type 2 VWD, 118 distinct sequence variations were 
identified, including new mutations in one- third of cases.45 These 
sequence variations were clustered in the A domains (types 2A, 2B 
and 2M) or D’- D3 domains of VWF (type 2N) and were missense 
mutations in a large majority of cases (95%).45 A total of 102 patients 
(88 families) with type 2N have been diagnosed (2007- 2014). In all 
cases, the VWF:FVIIIB assay was null or severely decreased, leading 
to low median FVIII:C levels of 19 (range 2- 45) IU dL−1.
The CRMW biologic platform has provided valuable data on the 
phenotype- genotype relationship in VWD. Studies are continuing to 
explore these relationships and further characterize VWD, partic-
ularly type 2 variants. The methodology is continually evolving to 
strengthen and broaden data capture. For example, bleeding score 
is now a mandatory inclusion criterion and NGS has been progres-
sively introduced since 2013. The CRMW does not collect prospec-
tive data on clinical events as these are collected in the national 
registry FranceCoag Network, which is not currently connected to 
the CRMW database. Connection of these databases, if regulatory 
issues can be overcome, would be an important extension of the 
CRMW biologic platform.
3.4 | Diagnosis in the United States
VWF testing is not standardized in the United States. For example, 
different centres use different VWF:RCo assays. In general, clini-
cians in the United States seem to be “over- educated” in what the 
VWF:RCo should be and less well educated on the importance of 
FVIII levels. Few centres can perform all of the increasingly complex 
subtyping tests, and most samples are sent to the Blood Center of 
Wisconsin for analysis. The use of standardized tests for diagnosis of 
VWD is not the standard of care because diagnosis has serious impli-
cations for life and health insurance. Premiums are higher for people 
with pre- existing conditions and hospitalization, and treatment of a 
pre- existing condition is not covered.
4  | TRE ATMENT OF V WD
4.1 | Towards pharmacokinetic population models 
for VWD: A lot “To WiN”?
Interindividual variation in the pharmacokinetic (PK) parameters of re-
placement FVIII in patients with haemophilia A is well documented.47,48 
This variation has stimulated interest in developing PK- guided treat-
ment regimens to optimize the treatment of patients with haemophilia 
A in the prophylactic setting,49,50 although the use of this approach in 
the perioperative setting, beyond determination of presurgery FVIII in 
vivo recovery (IVR), has received less attention. PK- guided dosing of 
VWF/FVIII concentrates has been shown to be effective and safe in 
patients with VWD undergoing surgery.51,52 However, little is known 
about the PK parameters during surgery in patients with VWD and the 
correlation between pre- and postsurgery IVR is weak.53
The “patient tailored pharmacokinetic- guided dosing of clotting 
factor concentrates in bleeding disorders (OPTI- CLOT)” study group 
is a multinational collaboration that aims to develop PK- guided 
perioperative treatment strategies for patients with bleeding disor-
ders. The OPTI- CLOT studies are using perioperative data from clin-
ical studies to construct a perioperative population PK model that 
can facilitate PK- guided iterative adaptive Bayesian dosing. During 
this procedure, individual PK parameters are iteratively updated by 
combining PK information (eg, dose, concentration, time) from the 
individual patient with a priori PK information from the population. 
To date, PK modelling has been applied to perioperative data from a 
Dutch retrospective study in patients with haemophilia A54 and PK 
modelling of perioperative VWD data is currently underway.
In the retrospective analysis of 119 haemophilia A patients un-
dergoing 198 surgical procedures in the Netherlands, 45% of FVIII 
plasma concentrations were below the target range during the first 
24 hours after surgery and 75% of the plasma concentration were 
above the target range after 6 days of hospitalization during periop-
erative management with FVIII concentrates54 (Figure 6). In addition, 
a reduction of 44% in the use of factor concentrates could have been 
achieved if plasma concentrations had been maintained within tar-
get levels in the perioperative setting.54 Population PK parameters 
were subsequently estimated in 75 adults undergoing 140 surgeries 
(median age: 48 years; median weight: 80 kg) and 44 children under-
going 58 surgeries (median age: 4.3 years; median weight: 18.5 kg)55 
who participated in the Dutch study.54 The model incorporated vari-
ations in PK parameters; eg, clearance decreased with increasing age 
(P < .01), increased in cases with blood group O (26%; P < .01), and 
there was a small decrease during major surgical procedures (7%; 
P < .01). The final PK model showed a good agreement between 
FVIII concentrations predicted by the model and those assessed by 
laboratory measurements.55 An ongoing, randomized controlled trial 
F IGURE  6 Achieved perioperative FVIII levels in a Dutch study 
in patients receiving clotting factor replacement therapy.54 FVIII, 
coagulation factor VIII; IU, international units
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is comparing iterative Bayesian PK- guided dosing with a standard 
dosing regimen in 60 patients with haemophilia A.56
Iterative Bayesian PK modelling of perioperative data from patients 
with VWD treated with VWF/FVIII in the WiN study (ClinicalTrials.gov 
Identifier: NCT00510042) is currently being evaluated in the To WiN 
study. Data for 103 patients (148 procedures) are being evaluated. The 
majority of patients have type 1 (52%) or 2 (42%) VWD and 6% have 
type 3. The To WiN study will also include a similar evaluation of pa-
tients treated with DDAVP in the WiN study. In addition, a prospective 
study of iterative Bayesian PK- guided dosing in VWD and surgical and 
dental procedures (OPTI- CLOT: TARGET) is planned.
Iterative Bayesian PK- guided dosing may allow individualization 
of perioperative therapy in patients with bleeding disorders and 
minimize under- or over- dosing during surgery. This approach has 
shown promise in patients with haemophilia A, and data from pa-
tients with VWD will soon be available.
4.2 | Surgery in VWD
Bleeding is a major surgical complication and is associated with mor-
tality rates of 20% in cases of severe bleeding.57 Approximately 75% 
to 90% of intraoperative and early postoperative bleeding can be 
attributed to technical factors.57 However, acquired or congenital 
coagulopathies may favour, if not directly cause, surgical haemor-
rhage in some cases.57
Bleeding rates during surgery in patients with VWD have been 
shown to be high in the absence58 and the presence59 of perioperative 
haemostatic therapy. Bleeding rates during surgery, in the absence 
of perioperative haemostatic treatment, have been assessed in 311 
patients (498 surgical procedures) who were diagnosed after surgery 
as definitive type 1 VWD (VWF:RCo 15- 30 IU dL−1) and possible type 
1 VWD (VWF:RCo 31- 49 IU dL−1).58 Major haemorrhages occurred in 
81 patients (26%) and 87 surgical procedures (17.5%), and there was 
no statistically significant difference between the percentage of type 
1 and possible type 1 VWD patients who had major haemorrhages 
(32.6% and 24.8%, respectively).58 In a multicentre, cross- sectional 
study	in	patients	with	VWF:RCo	≤30	IU	dL−1, bleeding complications 
were reported by 19 of 79 (24%) patients in 23 of 126 (18%) large joint 
procedures despite the use of perioperative haemostatic therapy in 
the majority of cases (81%).59 Possible causes of excessive bleeding 
in VWD patients during surgery include: anatomic changes due to 
prior bleeds, including neovascularization; insufficient haemostatic 
therapy; lack of stringent perioperative coagulation factor (VWF and 
FVIII) monitoring; lack of experience of surgeons/haematologists; and 
unnecessary use of anticoagulants in patients with bleeding disorder.
The main treatment options for the perioperative management 
of VWD patients are DDAVP and replacement factor concentrates. 
European Haemophilia Treatment Standardisation Board (EHTSB) 
recommendations for the practical use of DDAVP60 and factor con-
centrates61 in VWD patients undergoing invasive procedures have 
recently been published. The suitability of DDAVP should be deter-
mined by a test infusion in candidate patients.60 DDAVP is ineffec-
tive in type 3 VWD, and its use in type 2B remains controversial 
due to the possibility of thrombocytopenia.60 It can, however, be 
used effectively to cover minor surgery and dental procedures in 
most other VWD patients, although factor concentrate is gener-
ally preferred for major surgery.60 Concomitant use of antifibrino-
lytics should be considered in most surgical interventions covered 
by DDAVP, particularly those involving the mucous membranes.60 
DDAVP is not recommended in patients with ischaemic heart dis-
ease; a history of stroke and/or peripheral vascular disease; myocar-
dial infarction; heart failure; and hyponatraemia.60 Due to the risk of 
tachyphylaxis, DDAVP should not be given for more than 3- 5 days 
unless the patient can be monitored closely and switched to a con-
centrate if this occurs.60
Factor concentrates (VWF/FVIII or VWF) are the treatment 
of choice in patients in whom DDAVP is ineffective or contraindi-
cated.61 EHTSB recommendations on the perioperative dosing and 
monitoring of factor concentrates in VWD patients undergoing 
surgery, together with other published guidelines/recommenda-
tions, are summarized in Table 1. In the most recent publication, the 
EHTSB highlighted a number of important issues.61 For example, the 
ratio of VWF:RCo/FVIII:C in the concentrates varies significantly 
and doses of concentrate expressed in IU dL−1 are not interchange-
able. Therefore, the recommended dose of a given concentrate 
should be specific to that concentrate as the required dose can be 
completely different when another concentrate is used. Similarly, 
because various types of VWD are characterized by great variabil-
ity in VWF:RCo and FVIII:C, patients should have baseline values of 
VWF:RCo and FVIII:C measured before undergoing major surgery to 
plan treatment.61 For monitoring, FVIII:C seems to be more import-
ant than VWF:RCo.61 The parallel decay of VWF:RCo and FVIII:C 
curves with Wilate® (Figure 7), a VWF/FVIII with VWF:RCo/FVIII:C 
ratio of 1:1, may facilitate dosing and monitoring via either VWF:RCo 
or FVIII:C,62,63 while differing half- lives for VWF:RCo and FVIII:C in 
other concentrates might require monitoring of both factor levels. 
Tranexamic acid was also recommended by the EHTSB as a valuable 
adjunctive agent that may be used concomitantly with concentrates 
in patients with VWD undergoing surgery, particularly those involv-
ing mucous membranes.61
The perioperative management of patients with VWD can be 
challenging. Current treatment strategies are effective and will often 
include perioperative treatment with a factor concentrate. However, 
the dosing and monitoring of a given factor concentrate should be 
based on the properties of that concentrate and in accordance with 
its prescribing information, achieving critical target levels, but avoid-
ing sustained excessive FVIII:C levels.
4.3 | Surgery in the United States
PK analysis to guide dosing is not always performed and is generally 
considered to be of academic interest. DDAVP is often used if the pa-
tient is responsive and combined with factor concentrate as required. 
When DDAVP is used, it is important to monitor sodium levels to avoid 
water intoxication, particularly when fluid replacement during surgery 
is high. However, combination therapy is not the standard of care in 
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the United States and most institutions only use factor concentrates. 
Achieving haemostasis during surgery is the most crucial factor and 
should take precedence over the current “over- anxiety” about VWF 
and FVIII levels during surgery and potential thrombosis.
4.4 | Treatment in the United States
Available treatments in the United States are adjunctive therapies (DDAVP 
and antifibrinolytics) and factor replacement concentrates. Adjunctive 
therapies should not be overlooked. DDAVP is effective in many patients 
and may be particularly useful for the preoperative reversal of aspirin ef-
fects or in patients with coexisting renal insufficiency. Antifibrinolytics 
may be particularly useful in the treatment of gastrointestinal (GI) bleeds 
and in oral surgery. There are many different indications for concentrates. 
It is important to recognize that the US Food and Drug Administration 
(FDA) license a product for a specific indication, yet clinicians have the 
right to use any product any time for any reason. This raises the issue of 
potential litigation, and, to protect themselves, institutions may not per-
mit the use of products that are not specifically indicated.
5  | ANGIOGENESIS IN V WD
5.1 | VWF and angiodysplasia
The prevention and treatment of GI bleeding due to angiodysplasia 
is an important unresolved problem in the management of VWD 
TABLE  1 Guidelines on the dosing and monitoring of VWD patients undergoing surgery
Guideline/
recommendation
Dose, dosing frequency and monitoring
Minor surgery Major surgery
European 
Haemophilia 
Treatment 
Standardisation 
Board61
Preoperative	dose	should	target	FVIII:C	≥80-	100	IU	dL−1 
and	VWF:RCo	≥50	IU	dL−1
Postoperative doses should target trough levels of FVIII:C, 
and VWF:RCo should be >50 and 30 IU dL−1, respectively, 
on the day of surgery and for 3- 5 d or until wound healing 
is complete. Simple dental extractions may require only 1 
infusion immediately before the procedure, usually 
combined with tranexamic acid given orally for 7- 10 d; the 
recommended peak target levels of both FVIII:C and 
VWF:RCo for this indication is >50 IU dL−1
Preoperative	dose	should	target	FVIII:C	≥80-	100	IU	dL−1 
and	VWF:RCo	≥50	IU	dL−1
Postoperative doses should target trough levels of FVIII:C 
of 80- 100 IU dL−1 on the day of surgery, decreasing to 
50- 80 IU dL−1 on days 1- 7 and 30- 40 IU dL−1 by day 14 or 
until wound healing has been completed. For VWF:RCo, 
these levels are >50 IU dL−1 on the day of surgery, 
>30 IU dL−1 until day 14 or until wound healing is 
complete
Evidence- based 
recommendations 
on the treatment of 
VWD in Italy107
Daily or every other day doses of 30- 60 IU kg−1a of VWF/
FVIII to maintain FVIII:C levels >30 U dL−1 until healing is 
complete (usually 2- 4 d)
Daily doses of 50 IU kg−1a of VWF/FVIII to maintain FVIII:C 
levels >50 U dL−1 until healing is complete (usually 5- 10 d)
Consensus Statement 
on the treatment of 
VWD in Spain 108
40- 60 IU kg−1 every 24- 48 h to maintain FVIII:C >80- 
100 IU dL−1 on the first 2 d and >50 IU dL−1 on the 
following days
40- 60 IU kg−1 every 24- 48 h to maintain FVIII:C 
>30 IU dL−1, from 5 to 7 d
United Kingdom 
Haemophilia Centre 
Doctors 
Organization 109
FVIII:C should be monitored regularly in all major and most minor surgical procedures
FVIII:C	should	be	≥1.0	IU	mL−1 to cover major surgery and sustained above 0.5 IU mL−1 in the postoperative period
The VWF:RCo should be monitored in major surgical procedures, particularly in the perioperative period. The VWF:RCo 
should be maintained above 0.5 IU mL−1 in the perioperative period
USA National Heart, 
Lung, and Blood 
Institute23
30- 60 U kg−1 (loading doseb) and 20- 40 U kg−1 (mainte-
nance dose) every 12- 48 h
Trough VWF:RCo and FVIII >50 IU dL−1 for 3- 5 d
40- 60 U kg−1 (loading doseb) and 20- 40 U kg−1 (mainte-
nance dose) every 8- 24 h
Trough VWF:RCo and FVIII >50 IU dL−1 for 7- 14 d
FVIII:C, factor VIII coagulant activity; IU, international units; VWF:RCo, von Willebrand factor ristocetin cofactor activity; U, units.
aDosage indicated for VWD patients with FVIII:C/VWF:RCo levels <10 U dL−1.
bLoading dose is in VWF:RCo IU dL−1.
F IGURE  7 Wilate® is characterized by parallel VWF and 
FVIII decay curves.63 FVIII:C, coagulation factor VIII activity; 
IU, international units; VWF:Ag, von Willebrand factor antigen 
content; VWF:RCo, von Willebrand factor ristocetin cofactor 
activity
     |  13BERNTORP ET al.
patients. Angiodysplasia is characterized by degenerative lesions in 
the mucosal venules and capillaries in the GI tract associated with 
abnormal development of new blood vessels (angiogenesis).64-68
Gastrointestinal bleeding due to angiodysplasia is common in the 
elderly, with incidences ranging from 2.6% to 6.2% in the general 
population.69,70 Angiodysplasia- related GI bleeding is also a well- 
documented complication of VWD, although it occurs more fre-
quently at a younger age and almost exclusively in patients lacking 
high molecular weight multimers (HMWMs).65,71,72 In a 2- year, pro-
spective study of 107 patients, GI bleeding was much more frequent 
in patients with VWD characterized by a lack of HMWMs (type 2A) 
compared with type 2M VWD (Figure 8).
Indirect evidence implicating a lack of HMWMs in angiodysplasia- 
related GI bleeding in VWD has come from studies in acquired von 
Willebrand syndrome, especially in patients with aortic stenosis or 
lymphoproliferative disorders.67,68,73,74 Aortic stenosis is often accom-
panied by a lack of HMWMs due to the increased shear stress exerted 
by the stenotic valve, which stretches the VWF molecule and increases 
susceptibility to proteolysis by ADAMTS- 13.75,76 Surgical correction 
of valve stenosis restores a normal multimeric pattern and abolishes 
bleeding complications.74 The precise pathophysiological mechanisms 
underlying angiodysplasia- related GI bleeding in VWD have not yet 
been fully elucidated. However, in vitro data77 have shown that low 
VWF in Weibel- Palade bodies of endothelial cells can promote angio-
genesis and decrease vessel stability, which could lead to the vascular 
malformations typical of angiodysplasia.67
The treatment of GI bleeding in patients with VWD and angiodys-
plasia is challenging due to frequent recurrence and the severity of 
bleeding, which usually increases with age.67,68 Replacement therapy 
with plasma- derived VWF/FVIII concentrates is the mainstay for the 
episodic treatment of acute GI bleeding in VWD, although the clin-
ical effectiveness of VWF/FVIII concentrates in treating acute GI 
bleeds appears lower than for other bleeding sites.67,68 For example, 
a prospective study reported that a higher average daily dose (44 vs 
29 IU kg−1) and a longer duration of treatment (4.23 vs 1.93 days) 
were required for the treatment of GI bleeds compared with bleeds at 
other sites.78 A similar picture has emerged in studies evaluating VWF/
FVIII concentrates in secondary prophylaxis of recurrent GI bleeding, 
which have demonstrated the efficacy of VWF/FVIII concentrates 
but with lower efficacy than at other bleeding sites.67,68 In the largest 
published prophylaxis study, the VWD Prophylaxis Network retro-
spectively evaluated the efficacy of secondary prophylaxis with VWF/
FVIII concentrates in 59 patients with clinically severe VWD that were 
unresponsive to other treatments.79 Recurrent GI bleeding and ep-
istaxis were the most common reasons to initiate prophylaxis, with 
each accounting for 23.6% (13/55) of cases.79 Although the number of 
GI bleeds occurring during prophylaxis was significantly reduced, the 
percentage reduction in bleeding frequency (49%) was lower than that 
achieved for joint bleeding (86%).67,79
A possible explanation for the lower efficacy of VWF/FVIII con-
centrates in treating GI bleeds may be related to the fact that re-
placement therapy does not replenish VWF within endothelial cells 
and platelets (only plasmatic VWF) and the HMWM composition of 
concentrates may be less efficient in treating GI bleeds compared 
with bleeds at other sites.68,80
A number of alternative therapeutic approaches for the manage-
ment of recurrent GI bleeds have been explored.67,68 These include 
oestrogen, progesterone, octreotide, tranexamic acid and DDAVP, 
although these treatments do not appear to be effective based on 
the limited evidence currently available. Drugs with anti- angiogenic 
properties have also been used, such as thalidomide and very large 
doses of atorvastatin (up to 80 mg daily). Although a few cases have 
reported positive effects on the frequency of GI bleeding, larger con-
trolled studies are needed to establish the clinical usefulness of these 
therapies. Surgical approaches have not been shown to be consis-
tently effective because the angiodysplastic lesions are usually mul-
tiple and diffuse in the GI tract.
In summary, the prevention and treatment of GI bleeding due to 
angiodysplasia is an unresolved problem in the management of VWD 
patients. VWF/FVIII concentrates remain the mainstay therapy for 
the treatment of GI bleeds. Other strategies, such as rVWF and anti- 
angiogenic drugs, may have a future role in the prevention and treat-
ment of GI bleeding due to angiodysplasia, but need further exploration.
5.2 | Reproductive tissue alterations in VWD
Women with VWD are at increased risk of bleeds during the men-
strual cycle and during pregnancy.81 The most common symptom is 
menorrhagia (heavy menstrual bleeding), which is estimated to af-
fect 32%- 100% of women with VWD.23,81 Although VWF levels are 
known to rise in pregnancy, levels in women with VWD remain sig-
nificantly lower than in their healthy counterparts.81 Thus, women 
with VWD are at increased risk of bleeding complications associated 
with pregnancy and childbirth.
A study conducted in pregnant women with type 1 or type 2 VWD 
investigated management of VWD during pregnancy. For inclusion 
in the study, patients had to have had at least 2 previous bleeding- 
associated miscarriages or were experiencing bleeding during an on-
going pregnancy. Data are available for 61 patients (mean age of 32.7 
[±11.3]) with type 1 VWD who received replacement therapy as sec-
ondary prophylaxis or treatment during pregnancy. Live birth rate in 
treated patients was 80.3% (49 of 61) compared with a live birth rate of 
19.2% (28 of 146) prior to treatment (P < .0001). All 12 pregnancy losses 
F IGURE  8  Incidence rate/100 patient- years of spontaneous 
bleeding requiring treatment occurring in patients with type 2A or 
type 2M VWD.72 VWD, von Willebrand disease
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during replacement therapy occurred in the first trimester. Of the 118 
historical pregnancy losses, 98 (83.1%) occurred in the first trimester, 9 
(7.6%) occurred in the second trimester and 11 (9.3%) occurred in the 
third trimester.
Complex and dynamic changes in vasculature occur during the 
menstrual cycle and during pregnancy and angiogenesis plays a 
vital role.81-83 However, little is known about histological changes in 
women with VWD. To gain more insights into VWD during pregnancy, 
an animal study was initiated in 2016 and is due for completion in 
2019. Meishan pigs84 suffering from type 3 VWD as well as type 1 
VWD, and healthy controls are being studied. Collection of tissue from 
reproductive organs is planned for different stages of the menstrual 
cycle in non- pregnant animals of reproductive age, implantation and 
placentation, respectively. Parameters being assessed include forma-
tion of blood vessels by haematoxylin and eosin staining, localization 
of angiogenesis mediators and receptors by immunohistochemis-
try, presence of causal mutations and functional gene analysis using 
geneMANIA. Various angiogenic factors are being investigated in the 
study, including angiopoietin- 1 (ANG- 1), which promotes vascular 
maturation,83 vascular endothelial growth factor (VEGF), which is vital 
for vascular growth,83 and the αVβ3 integrin, which is a cell adhesion 
receptor.85
Preliminary results from 3 reproductive organs—uterus (endome-
trium), ovary and oviduct—showed significantly fewer blood vessels 
with small lumens, whereas type 3 VWD animals have more thin- 
walled vessels, which appear dilated and filled with red blood cells 
(data not shown). Compared with control animals, there is decreased 
or even absent VWF staining in the uterine glands and endometrium 
of VWD animals. While type 3 samples show strong αVβ3 staining, 
this is in clear contrast to type 1 samples. Ongoing studies include 
comparative quantification of the protein expression by real- time 
polymerase chain reaction (RT- PCR) to further elucidate the role of 
VWF in female reproduction and angiogenesis.
In conclusion, study results in VWD patients during pregnancy 
demonstrated a dramatic decrease in rate of pregnancy loss under 
VWD replacement therapy. Detailed analysis of the expression and 
localization of angiogenic factors in an animal model suggests that 
disrupted formation of vessels in several female organs may be an 
important pathogenic factor.
6  | V WF INHIBITORS
6.1 | Detecting inhibitors in VWD: an academic 
question?
Anti- VWF inhibitors are a rare complication of replacement therapy 
that negates the haemostatic response to infused VWF concen-
trates.86 Inhibitors develop in an estimated 5.8%- 9.5% of patients 
with type 3 VWD and have very rarely been reported in patients 
with other VWD types.86,87 In a retrospective analysis of the Italian 
Association of Hemophilia Centers (AICE), 96 of 1650 VWD pa-
tients had type 3 VWD (5.8%). Anti- VWF inhibitors were identified 
in 6 type 3 VWD patients, which correspond to 6.2% (6/96) of type 
3 patients and 0.4% (6/1650) of the total VWD population.88 In 
contrast, FVIII inhibitors developed in 19.2% (316/1688) of patients 
with severe haemophilia A.88
These anti- VWF inhibitors are alloantibodies and might be related 
to deletions of the VWF gene, although it is important to recognize 
that not all gene deletions are associated with inhibitor development. 
In the late 1980s, gene defects associated with inhibitor development 
were identified using the Southern blot technique.89,90 In 1 study, ho-
mozygous complete VWF gene deletions were identified in the 2 of 
the 19 type 3 VWD patients who developed inhibitors.89 In another 
study, complete homozygous and heterozygous deletions were found 
in 6 of 10 type 3 VWD patients.90 In the 1990s, 1 complete homo-
zygous and 1 partial heterozygous deletion among 28 type 3 VWD 
German patients from 32 families were identified,91 whereas 1 com-
plete heterozygous VWF gene deletion was identified among 5 type 3 
VWD Italian patients.92 A common 253- kb deletion involving VWF and 
TMEM16B (ANO2) was subsequently identified in German and Italian 
patients with severe type 3 VWD.93 In addition, partial homozygous 
VWF gene deletions including exons 1- 3, 6- 16, 42, 33- 38, 22- 43, 23- 
52 and 17- 18 have been described in 7 type 3 VWD patients; among 
these defects, only the Alu- mediated deletion of exons 1- 3 was found 
in several patients, constituting the most common defect in type 3 
VWD patients in Hungary.94
Whereas the Bethesda method with the Nijmegen modification is 
well established in the laboratory measurement of inhibitors in patients 
with haemophilia A, no general consensus has been reached for diag-
nosing anti- VWF inhibitors. Mix test assays, which are available in a 
small number of expert laboratories, mimic the Bethesda assays used 
in haemophilia A by measuring VWF/FVIII activities in patient- normal 
pool plasma after 2- 4 hours incubation at 37°C. The titre of anti- VWF 
inhibitor is calculated by the actual dilution of VWD plasma inhibiting 
50% of normal plasma pool diluted 1:2 compared with control mixture 
(buffer instead of patient plasma). Several solid phase tests have been 
proposed, but these are not frequently used. The inhibitory activity of 
VWF inhibitors should be assessed by a range of measures, such as 
RIPA in normal platelet- rich plasma, anti- VWF:Ag, anti- VWF:RCo, anti- 
VWF:CB and anti- FVIII. However, antibodies might also occur against 
“mute” regions of VWF molecules that cannot be identified with func-
tional assays. An assay to test anti- VWF antibodies using a sandwich 
ELISA (Ex- VWF- Plasma- HRP goat anti- human IgG- IgM) appears to be 
more sensitive than functional assays.95 The outcome of an ongoing 
initiative of an ISTH subcommittee on VWF may lead to a more stan-
dardized approach to laboratory measurement of VWF inhibitors.
In most reported cases, antibody development is heralded by 
poor clinical response to replacement therapy accompanied by lower 
than expected recovery of VWF with the absence of the delayed and 
sustained raise of FVIII (secondary response to VWF). In cases where 
inhibitor titre is relatively low, it is not difficult to treat soft- tissue 
bleeds and to prevent bleeding in surgery. In patients with high- titre 
inhibitors, replacement therapy is not only ineffective, but it may 
also trigger life- threatening anaphylactic reactions associated with 
activation of the complement system.96 A rise in antibody levels is 
     |  15BERNTORP ET al.
usually seen 5- 10 days after replacement therapy with VWF concen-
trates, with features typical of a secondary response to a foreign an-
tigen. Recombinant FVIII (no VWF) was effective in a type 3 patient 
with inhibitors undergoing emergency abdominal surgery.97 Other 
possible therapeutic approaches are recombinant activated factor 
VII (rFVIIa) or a combination of rFVIII and rFVIIa.98-100 However, the 
use of rFVIII and rFVIIa in combination should take into account the 
possibility of thrombosis.100
The 3WINTERS- IPS study—type 3 VWD International Registries 
and Inhibitor Prospective Study (3WINTERS- IPS, 2011- 2018) has 
been set up to record clinical and laboratory data on a large cohort 
of at least 250 type 3 VWD patients at a network of European and 
Iranian centres.101 The study comprises 3 phases (Figure 9). In the 
first phase, ~250 type 3 patients were retrospectively identified. 
In the second phase, the diagnosis will be confirmed by centralized 
laboratory evaluation of the patients identified in the retrospective 
phase. Those patients with confirmed diagnosis of type 3 VWD 
(≥150	expected)	will	then	enter	a	2-	year,	prospective	third	phase	of	
the study. So far, a total of 266 patients (146 Europeans and 120 
Iranians) have been identified with type 3 VWD in the retrospective 
phase and laboratory samples are undergoing confirmatory central-
ized testing.
Even though the development of VWF inhibitors against re-
placement therapy is rare in patients with VWD, it is an important 
limitation of current therapy. 3WINTERS- IPS will provide important 
information on VWF inhibitors in type 3 patients and is expected to 
improve our understanding of the diagnosis and treatment of pa-
tients with type 3 VWD who develop inhibitors.
6.2 | Case report of immune tolerance induction in 
2 brothers with VWF inhibitors
Brother 1 presented as a 7.5- year- old boy diagnosed with VWD at 
the age of 2.5 years after presenting with a foot contusion. At the age 
of 4 years, he was hospitalized due to prolonged epistaxis and treated 
with VWF/FVIII concentrate every 12 hours. During this intensive 
treatment, he developed mild shortness of breath responsive to al-
buterol, but subsequently did well with on- demand therapy.
Brother 2 presented as a 20- month- old boy diagnosed with VWD 
at birth (asymptomatic) due to the family history of VWD. He expe-
rienced frequent epistaxis and iron deficiency anaemia, which was 
treated on- demand. He received about 15 prior VWF/FVIII concen-
trate infusions. Vague allergic symptoms were reported initially.
Genetic testing confirmed that both brothers had a large ho-
mozygous deletion, VWFc.658_7887del, consistent with type 3 
VWD. Prophylaxis was initiated for each with VWF/FVIII concen-
trate, but brothers manifested allergic symptoms, which worsened 
with subsequent doses. The older brother had mild shortness 
of breath; the younger experienced progressive symptoms of 
shortness of breath, urticaria, tachycardia and mild hypotension. 
Symptoms were responsive to intravenous diphenhydramine. 
Despite trialling a different VWF/FVIII concentrate, similar symp-
toms were observed, so further use of VWF/FVIII concentrate was 
avoided.
While abroad, both were treated with a highly purified VWF con-
centrate. Although they did not develop allergic symptoms, bleed 
treatment was increasingly less effective. A mixing study confirmed 
the presence of neutralizing alloantibodies.
Skin prick testing and intradermal testing to VWF/FVIII concen-
trates and excipients were not suggestive of an IgE- mediated aller-
gic response. There is currently no standard approach to immune 
tolerance induction (ITI) in patients with VWF inhibitors. Following a 
graded challenge for the older brother and a 12- step desensitization 
protocol for the younger brother, ITI with 50 VWF:RCo IU kg−1 daily of 
a 1:1 VWF/FVIII concentrate and mycophenolate mofetil 600 mg m−2 
twice daily was initiated in both brothers.
During approximately 8 months of treatment, the brothers re-
ceived rFVIIa and aminocaproic acid to treat ongoing epistaxis, gin-
gival bleeding and occasional injury. FVIII infusion and platelets were 
also used for surgical procedures. Due to the ongoing symptoms and 
presence of VWF inhibitors, the ITI regimen was changed to ritux-
imab 375 mg m−2 (4 doses) with continued VWF/FVIII concentrate 
treatment. Subsequent single rituximab doses were administered 
with B- cell recovery. This resulted in modest reduction in VWF in-
hibitor titres in both brothers and an improvement in clinical symp-
toms (Figure 10).
7  | MEMORIES OF MARGARETA 
BLOMBÄCK ON RESE ARCH ON/ABOUT 
ÅL AND AND V WD
I have had the great privilege of being involved in 3 research trips to 
the Åland Islands in 1957, 1977 and 1992.102
Prior to the first trip in 1957, Inga Marie Nilsson and I had investi-
gated many Swedish families with “pseudohemophilia” and found low 
FVIII and a prolonged bleeding time.103 In addition, Birger Blombäck 
and I had purified a plasma fraction (Fraction I- 0) that contained 
F IGURE  9 Overview of the 3WINTERS- IPS study. BAT, 
bleeding assessment tool; FVIII, coagulation factor VIII; VWD, von 
Willebrand disease; VWF, von Willebrand factor
Phase 1 (36 months)
Retrospective registries 
of VWD3 patients
Phase 2 (12 months)
Central confirmation
of VWD3 diagnosis
in expert labs 
Phase 3 (24 months)
Prospective observational 
clinical study in confirmed
VWD3 patients only
250
VWD3
≥ 150
VWD3 
confirmed
Central lab evaluation
1) VWF and FVIII activities
2) Anti-VWF inhibitors
3) Molecular defects
1) Bleeding history 
(with bleeding score)
2) Basic VWF and FVIII
3) Presence of inhibitors
4) Exposure to concentrates
Follow-up in at least
150 VWD3
1) Repeated BAT
2) Number and types of 
bleeding patients
3) Surgery
4) Prophylaxis
5) Efficacy and safety of 
VWF concentrates
6) Inhibitors
Europe
125 VWD3
Iran
125 VWD3
16  |     BERNTORP ET al.
fibrinogen and FVIII, which stopped bleeding in patients with VWD, 
normalized FVIII and corrected the prolonged bleeding time.102 On 
the 1957 trip to the Åland Islands, I was joined by colleagues from 
Stockholm (Professor Erik Jorpes and Inga Marie Nilsson) in collab-
oration with Birger Blombäck and Stig- Arne Johansson. We wanted 
to investigate whether the “pseudohemophilia” in Åland and Sweden 
was the same. We analysed data from Family S described by Erik 
von Willebrand in 1926 and some other families. Investigations of 
15 living patients showed that FVIII levels were 30%- 60% of normal, 
platelet activity was normal, and there were no capillary defects. 
Infusion of Fraction I- 0 to 1 patient resulted in normalization of FVIII 
activity and the prolonged bleeding time as we had previously seen 
in Swedish patients.104
In 1977, I returned to the Åland Islands together with Dag Nyman 
(then working in Stockholm). By this time, VWF:RCo and VWF:Ag 
assays were available. We found that the families could be divided 
into 4 categories102,105: the survivors of family S, the original fam-
ily, from Föglö, had the characteristics of type 1 VWD; ie, they had 
similarly decreased levels of VWF:Ag and VWF:RCo in addition to 
normal or decreased levels of FVIII. One family had a “pure” platelet 
dysfunction (cyclooxygenase defect), 1 family had a mixture of type 
1 VWD and a cyclooxygenase defect, and 1 family had an “aspirin” 
type platelet dysfunction.
On my final research visit to the Åland Islands in 1992, I was 
joined by Dag Nyman (now again in Åland) and Zhiping Zhang from 
Stockholm. We collected DNA in VWD families and found exon 18 
mutation in those with bleeding symptoms in Family S and 2 other 
families as well as in a 2- year- old boy with severe VWD (homozy-
gote) and his parents (heterozygotes).102,106 One cytosine deletion in 
exon 18 was detected in all the families. Linkage analysis and gene-
alogical studies suggest that the deletion in these families probably 
has a common origin also with the Swedish patients.
Pier Mannucci concluded by paying tribute to the enormous 
contribution that Margareta had made to the scientific and clinical 
understanding of VWD. This sentiment was shared by all pres-
ent, including Gerda S, the non- affected sister of the index case, 
Hjördis S.
8  | CONCLUSIONS
The Fifth Åland Island meeting was a great success as were the previ-
ous meetings on these beautiful islands. The soul of the meeting is 
to convene a nice blend of international leaders in the field of VWD 
and younger, interested and motivated physicians. The scientific 
agenda is translational going from molecular genetics and molecules 
via laboratory issues and pharmacokinetics to epidemiology and clini-
cal challenges, and, of course, history. The meeting has a high scien-
tific standard with plenty of room for discussions and networking. 
However, there is also another dimension that is unique: a visit to 
Hjördis’ house and graveyard gave a fundament for those who con-
tribute to future research and development in the understanding and 
treatment of VWD.
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F IGURE  10 Anti- VWF antibodies measured by ELISA during 
ITI. ELISA, enzyme- linked immunosorbent assay; FVIII, coagulation 
factor VIII; ITI, immune tolerance induction; MMF, mycophenolate 
mofetil; VWF, von Willebrand factor
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